Other

Cancer incidence in Iran in 2014: Results of the Iranian National Population-based Cancer Registry

Cancer Epidemiology · 2019112,131 new cancer cases registered in 2014
Roshandel G, Ghanbari-Motlagh A, Partovipour E, Salavati F, Hasanpour-Heidari S, Mohammadi G, et al. Cancer Epidemiology. 2019. 61:50-58
Study type
Other
Study name
INPCR 2014
Design
Descriptive report based on the national population-based cancer registry (not an interventional study)
Sample size
112,131 new cancer cases registered in 2014
Source
Cancer Epidemiology · 2019

In plain words

This report gives the first results of Iran's national cancer registry for 2014 and shows that more than 112 thousand new cancer cases were recorded in the country that year. In men, cancers of the stomach, prostate and bowel (colon and rectum) were the most common; in women, breast cancer, bowel cancer and stomach cancer. Rates of oesophageal, stomach and lung cancer were higher in the north and north-west of the country.

Key results

112,131 cases, of which 60,469 (53.9%) were in men
Total new cancer cases registered in 2014
76,568 cases (68.28%)
Diagnosis with microscopic verification
177.44 vs 141.18
ASR of all cancers in men vs women (per 100,000)
Stomach (21.24), prostate (18.41) and colorectal (16.57)
Most common cancers in men (ASR)
Breast (34.53), colorectal (11.86) and stomach (9.44)
Top three cancers in women (ASR)
1.78
ASR of cervical cancer in women
High incidence of oesophageal, stomach and lung cancers in the north and north-west of Iran
Geographical variation
As indicated by the findings

Study population

The total population of Iran in 2014 was 76,639,000. The Iranian National Population-based Cancer Registry (INPCR) covered 30 of the country's 31 provinces (98% of the total population). Only newly diagnosed primary malignant tumours were registered. The main data sources were pathology centres, hospitals and death registries.

Endpoints

Age-standardised incidence rates (ASR) per 100,000 people, at national and subnational (provincial/regional) level. Quality control and data analysis were done with CanReg-5 software.

Safety and side effects

This was not an interventional study and no treatment adverse events are reported.

Clinical significance and place in guidelines

This study is an epidemiological report and does not directly change patient treatment. Its data can be useful for health planning, prioritising screening and prevention, and allocating resources, given that the pattern of the most common cancers in Iran differs from the global pattern and varies geographically. Clinical recommendations and related guidelines should be checked separately.

Limitations

According to the abstract, only 68.28% of cases had microscopic verification. The study is descriptive and covers 2014 only. Other limitations (such as the completeness of registration in each province) should be checked in the full text.

This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.